Clinical Trial Update: Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck [Phase 1]

View source ↗

Summary

A Phase I trial of Olaparib in combination with cisplatin-based chemoradiotherapy for head and neck squamous cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Lynparza (olaparib)

Snippet

Sponsor: University College, London | Conditions: Carcinoma, Squamous Cell | Phase 1 | Status: WITHDRAWN